BIOLINERX     Print Page  Close Window

SEC filings
SC 13G/A
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP filed this Form SC 13G/A on 02/16/2016
Entire Document
 
 
CUSIP No.  09071M106
 SCHEDULE 13G/A
Page 8 of 8 Pages

 

 

EXHIBIT A

JOINT FILING AGREEMENT

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendment thereto, with respect to the beneficial ownership by each of the undersigned of the Ordinary Shares of BioLineRx Ltd. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning the others. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 16, 2016.

 

 

       
  ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP
       
  By: OrbiMed Israel GP Ltd., its General Partner
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title: Director
       
  ORBIMED ISRAEL GP LTD.
       
  By: Nissim Darvish
    Name: Nissim Darvish
    Title:  Director